| 1 |
28502922 | Design, Synthesis, and Structure-Activity Relationship Study of Epoxysuccinyl-Peptide Derivatives as Cathepsin B Inhibitors. | 2017 Aug 1 |
1 |
| 2 |
26388830 | Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate. | 2015 |
1 |
| 3 |
24595198 | Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. | 2014 |
1 |
| 4 |
21613740 | The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity. | 2011 |
1 |
| 5 |
22046434 | Overexpression of a minimal domain of calpastatin suppresses IL-6 production and Th17 development via reduced NF-κB and increased STAT5 signals. | 2011 |
1 |
| 6 |
16339296 | Zymogen activation in a reconstituted pancreatic acinar cell system. | 2006 May |
1 |
| 7 |
11776436 | L-2,5-dihydrophenylalanine, an inducer of cathepsin-dependent apoptosis in human promyelocytic leukemia cells (HL-60). | 2001 Oct |
1 |
| 8 |
10098844 | Distinct secretases, a cysteine protease and a serine protease, generate the C termini of amyloid beta-proteins Abeta1-40 and Abeta1-42, respectively. | 1999 Apr |
1 |
| 9 |
9742009 | Cysteine protease inhibitor, E-64d, prevents in vitro cerulein- induced trypsinogen activation. | 1998 Sep |
1 |